NEW YORK, May 15 – Integrative Proteomics said Tuesday that four companies are planning to take equity stakes in the Toronto-based company.
Bruker AXS, Bruker BioSpin, Bruker Daltonics, and Aurora Biosciences all plan to make a strategic equity investment in Integrative Proteomics, the company mentioned in a statement announcing the company’s recent activities. Integrative Proteomics did not offer any details about the size of the stakes. A spokeswoman was not immediately available for comment.
Integrative Proteomics uses products from the three Bruker companies and Aurora Biosciences in its efforts to determine protein structures.
In the statement, Integrative Proteomics said it completed a first pass interrogation of proteins responsible for intracellular functions in Staphylococcus , a disease bacterium, using its proprietary platform, which integrates mass spectrometry, X-ray crystallography, and nuclear magnetic resonance.
“Our analysis represents the first step toward reconstructing the inner workings of a bacterium in order to understand how to make better antibacterial drugs,” said Aled Edwards, Integrative Proteomics’ chief scientist. “We can now leverage our ability to analyze function and structure on genome-scale projects in other therapeutic areas, including viral and human diseases.”
Several companies and public efforts have been engaged in sequencing Staphylococcus.
In its project, Integrative Proteomics said it analyzed more than 1,700 genes and made nearly 1,000 different bacterial proteins in sufficient quantity and quality to interrogate their function and structure. The company then reconstructed the functional network of the proteins and their interactions.
Integrative Proteomics has 45 employees and has previously received investment funds from CC Capital Partners, Eastern Technology Seed Investment Fund, and Lombard Odier.